Slit3 down-regulation in HCC might indicate a poor response of the tumor cells to chemotherapy, and subsequently, treatment with recombinant Slit3 is a novel potential therapeutic approach in patients with HCC, as well as other cancer types where Slit3 is repressed. Here, SLIT3 is linked to hepatocellular carcinoma.